Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,846 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Disease Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait

NCT06688578
View directory record Official record
Conditions
Vestibular Disorder, Aging
Interventions
Subperceptual Stimulus, Sham Comparator
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Comparison of Outcomes Between Early Physical Therapy Intervention and Usual Care Following Anterior Cervical Fusion Surgery

NCT01519115
View directory record Official record
Conditions
Cervical Spine Degenerative Disc Disease, Fusion of Spine, Cervical Region
Interventions
early physical therapy intervention, usual care
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion

NCT01714804
View directory record Official record
Conditions
Stenosis, Spondylosis, Degenerative Changes
Interventions
Accell Evo3 Prospective Use
Device
Lead sponsor
SeaSpine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durango, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 30, 2026, 4:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

NCT01782352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 30, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

NCT00065455
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 4:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445
View directory record Official record
Conditions
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions
OpCT-001
Biological
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 4:24 AM EDT
Completed No phase listed Observational

Osteocel® Plus in Anterior Cervical Discectomy and Fusion (ACDF)

NCT00942045
View directory record Official record
Conditions
Degenerative Disc Disease in Cervical Spine
Interventions
Biologic - Osteocel Plus
Biological
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 70 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
17
States / cities
La Jolla, California • Redwood City, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Study of NGM621 in Participants With Geographic Atrophy

NCT04014777
View directory record Official record
Conditions
Geographic Atrophy
Interventions
NGM621
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

NCT03861234
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
BI 836880
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • New York, New York • Eugene, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

NCT03815916
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

NCT04577352
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Vatiquinone, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 30, 2026, 4:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Visual Remapping to Aid Reading With Field Loss

NCT03848663
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Traditional Remapping, Personalized Remapping
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

NCT01632527
View directory record Official record
Conditions
Age Related Macular Degeneration, Macular Degeneration, AMD
Interventions
HuCNS-SC cells
Drug
Lead sponsor
StemCells, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 30, 2026, 4:24 AM EDT
Completed No phase listed Observational

Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics

NCT00831961
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Conjunctival and nasopharyngeal bacteria cultures
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 30, 2026, 4:24 AM EDT
Completed No phase listed Observational

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

NCT01644513
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
55 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Sep 30, 2026, 4:24 AM EDT
Enrolling by invitation No phase listed Observational

Implementation of the NEDS EyeCTester App

NCT04607369
View directory record Official record
Conditions
Optic Nerve Disease, Macular Disease, Visual Pathway Disorder
Interventions
EyeCTester
Device
Lead sponsor
Neuro-Eye Diagnostic Systems, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
Drug
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 30, 2026, 4:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antioxidant Systems and Age-Related Macular Degeneration

NCT00668213
View directory record Official record
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
55 Years to 85 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Ziv-aflibercept Efficacy in Better Regulating AMD

NCT03423823
View directory record Official record
Conditions
Wet Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab
Drug
Lead sponsor
Kapil Kapoor
Other
Eligibility
50 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Sep 30, 2026, 4:24 AM EDT
Not listed No phase listed Observational

Validation of Consumer Activity Monitors in Postoperative Total Arthroplasty Patients

NCT03958370
View directory record Official record
Conditions
Arthropathy of Knee, Arthritis Knee, Arthritis, Degenerative
Interventions
Fitbit
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 30, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)

NCT00109499
View directory record Official record
Conditions
Macular Degeneration
Interventions
AdGVPEDF.11D
Drug
Lead sponsor
GenVec
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Boynton Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Sep 30, 2026, 4:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

NCT02291887
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Aflibercept
Drug
Lead sponsor
Associated Retinal Consultants, Michigan
Other
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Sep 30, 2026, 4:24 AM EDT